Case Details
- Citation: [2025] SGHC 12
- Court: High Court (General Division)
- Originating Claim No: 192 of 2022
- Summons No: 1022 of 2024
- Judgment Date: 20 January 2025
- Hearing Dates: 18 November 2024 (Judge Case Conference); 29 November 2024 (as reflected in the judgment header)
- Judge: Kwek Mean Luck J
- Applicant/Claimant: Banner (China) Investment Company Limited
- Respondent/Defendant: Ang Jimmy Tjun Min
- Legal Area: Civil Procedure; Evidence; Expert evidence (handwriting analysis); specimen signatures
- Statutes Referenced: Evidence Act 1893 (2020 Rev Ed) (ss 73 and 75)
- Key Issue (as framed by the judgment): Selection and verification of specimen signatures for submission to a handwriting expert; manner of verifying authenticity of authorship of specimen signatures
- Judgment Length: 13 pages, 3,056 words
- Procedural Context: Single Application Pending Trial (SAPT) in OC 192; directions for obtaining signature samples for a common expert from the Health Sciences Authority (HSA)
Summary
Banner (China) Investment Company Limited v Ang Jimmy Tjun Min [2025] SGHC 12 concerns a procedural dispute in a civil claim where the authenticity of a disputed signature is central to liability. The claimant, Banner, sued for repayment of a very large loan sum, relying on an audit confirmation allegedly signed by the defendant, Mr Ang, on 3 July 2020. Mr Ang denied signing the audit confirmation and pleaded that the signature was forged. To resolve the authorship dispute, the parties sought a handwriting analysis by a common expert from Singapore’s Health Sciences Authority (HSA).
The High Court (Kwek Mean Luck J) had earlier directed that HSA be appointed as the common expert. However, the parties then became deadlocked on how to obtain the signature specimens that HSA would use for comparative analysis. The defendant argued for a process that would allow him to choose or control which documents were used as specimen signatures. The court rejected that approach and issued directions requiring both parties to work with a corporate secretarial services provider (Boardroom Corporate Services (Johor) Sdn Bhd) to generate a list of at least 15 documents that Mr Ang clearly signed, including documents whose signatures Mr Ang had not seen.
In substance, the court emphasised the integrity of the specimen-selection process and the need to ensure authentic authorship of the specimen signatures, while holding that the Evidence Act does not confer on a party a right to select the specimen signatures for comparison. The court’s directions sought to balance fairness (allowing Mr Ang to raise concerns about particular documents) with procedural safeguards to prevent selective or potentially biased specimen selection.
What Were the Facts of This Case?
Banner’s claim in OC 192/2022 is for repayment of a loan amounting to S$11,092,061.53. The claimant’s case depends heavily on an “Audit Confirmation” dated 3 July 2020. Banner alleges that the audit confirmation was signed by Mr Ang and that it confirms Mr Ang’s indebtedness to Banner in the sum of HK$65,955,196.76 as at 31 March 2018 (equivalent to the Singapore dollar figure claimed). Mr Ang’s defence is that the sum was advanced to him as a gift, and, critically for present purposes, that he did not sign the audit confirmation. He therefore pleaded that the signature on the audit confirmation was forged.
Because handwriting authorship was contested, Banner proposed that the parties appoint an expert from the Health Sciences Authority (HSA) to conduct a handwriting analysis of the signature on the audit confirmation. Mr Ang disagreed with Banner’s proposal and instead suggested that a forensic consultant from Malaysia be appointed as the common expert. The disagreement led Banner to file a Single Application Pending Trial (SAPT) in HC/SUM 1022/2024, seeking, among other things, an order that the court appoint an HSA expert as the common expert for the handwriting analysis. Mr Ang opposed that application.
At a Judge Case Conference on 7 May 2024, the parties indicated agreement to an HSA common expert. The court therefore ordered that HSA be appointed and provided consequential directions on the timelines for obtaining the HSA expert’s report. After that, however, the parties failed to agree on the process for obtaining signature samples (specimen signatures) to be submitted to HSA. The court had earlier given directions on identifying signature specimens from documents filed in Singapore and Hong Kong proceedings, and on obtaining specimens from other sources if HSA required a time period outside those court documents. The court also contemplated obtaining documents from a company in Johor Bahru, Malaysia, in which the parties were involved and in which Mr Ang would have signed certain documents.
As the matter progressed, the parties encountered practical difficulties obtaining the originals of documents signed by Mr Ang for the Hong Kong proceedings that would satisfy HSA’s requirements. Banner proposed that the parties make a joint request to the corporate secretarial services company (BCS) for originals of company documents in three Johor Bahru companies (“Three JB Companies”) in which Mr Ang was a director. Mr Ang disagreed. His solicitors conveyed to Banner that it was “crucial” that Mr Ang chooses the documents to be examined by HSA because it was his signature that was in dispute. This impasse was brought before the court at the 18 November 2024 Judge Case Conference, prompting the directions that Mr Ang later appealed.
What Were the Key Legal Issues?
The central legal issue was not whether handwriting analysis was appropriate, but how the specimen signatures should be obtained and verified for use by the HSA expert. The court had to decide whether, in a disputed-signature context, the defendant could insist on selecting the specimen signatures/documents that would be provided to the expert for comparative analysis, or whether the process should be structured to ensure integrity and authenticity without granting such a selection right.
Related to that was the evidential question of how authenticity of authorship should be established for specimen signatures. The court needed to ensure that the specimen signatures used for comparison were genuinely made by the person whose authorship was disputed (Mr Ang). This required attention to the Evidence Act provisions governing the use of signatures for comparison and the circumstances in which a signature can be treated as a comparison signature.
Finally, the court had to manage procedural fairness in expert evidence. While the defendant’s concern was that he should be able to verify that the specimens were authentic, the court had to determine what safeguards were necessary to prevent the specimen-selection process from being manipulated or “tailored” to produce a favourable outcome. The issue therefore involved balancing integrity of the expert process against the defendant’s right to participate meaningfully in the preparation of the evidence that would be used against him.
How Did the Court Analyse the Issues?
Kwek Mean Luck J approached the dispute by first setting out the procedural history and the directions already given for appointing HSA as the common expert. The court then focused on the specific impasse at the 18 November 2024 Judge Case Conference: Banner’s proposal to obtain at least 15 specimen signatures through BCS from the Three JB Companies, versus Mr Ang’s proposal to use 12 specimens he had obtained from one of those companies. The court observed that Banner expressed concern about the integrity of Mr Ang’s proposed process, particularly because Mr Ang’s signature was the one in dispute and the process could become selective.
In analysing integrity, the court identified a key principle: there must be integrity in the process of obtaining signature specimens for the common expert. The court reasoned that integrity would be eroded if Mr Ang were allowed to be selective about which signature specimens were submitted to HSA. The court’s concern was that selective specimen selection could undermine the reliability of the comparative exercise, even if the defendant’s stated objective was to verify authenticity. In other words, the court treated the specimen-selection process itself as part of the evidential reliability framework, not merely a logistical step.
Second, the court considered the need for authentic signature specimens to be surfaced and identified. In the present case, it was not disputed that Mr Ang was a director in the Three JB Companies, that he signed documents in that capacity, and that there would have been certain documents he must have signed as director. These facts supported the feasibility of identifying authentic specimen signatures. Importantly, the court’s directions were designed to allow Mr Ang to provide his views on the list of documents identified by BCS, so that any specific concerns about particular documents could be surfaced for the court’s consideration. This addressed the defendant’s fairness concern without granting him a unilateral selection power.
Third, the court addressed Mr Ang’s reliance on Malaysian authority, Tung Kean Hin & Another (as executor for the estate of Tung Leong Geok, deceased) v Yuen Heng Phong (as administrator for the estate of See Ngan Sang @ Lee Ngan Sang) [2019] 2 MLJ 334. In Tung Kean Hin, the court highlighted the importance of considering whether a plaintiff was the author of specimen signatures provided for examination, because specimen signatures form the basis for the handwriting expert’s comparative analysis. The High Court accepted the general point that authenticity of authorship is crucial. However, it held that the dicta did not support the proposition advanced by Mr Ang—namely, that a party has a right to select specimen signatures for handwriting analysis. The court treated Tung Kean Hin as reinforcing the authenticity requirement rather than creating a selection right.
Finally, the court relied on the Evidence Act to resolve the selection-right argument. Section 75 of the Evidence Act 1893 (2020 Rev Ed) provides that a disputed signature can be compared to a signature that is “admitted or proved to the satisfaction of the court to have been … made by that person”. The court reasoned that this statutory structure does not confer on Mr Ang a right to select the specimen signatures. Even if a comparison signature is not admitted, it can still be used if it is proved to the court’s satisfaction that it was made by the person. Thus, the court framed the issue as one of evidential admissibility and proof, not party autonomy over the specimen pool.
In applying these principles, the court concluded that the defendant’s proposed process effectively amounted to selection of specimen signatures, even if he characterised it as merely a verification exercise. The court therefore rejected the idea that authenticity concerns translate into a right to choose which documents are provided to the expert. Instead, the court endorsed a process that would (i) preserve integrity by using BCS to generate a list of documents that Mr Ang clearly signed, (ii) include documents whose signatures Mr Ang had not seen (to reduce the risk of tailored selection), and (iii) allow Mr Ang to raise concerns about particular documents once the list was produced.
What Was the Outcome?
The court issued directions at the 18 November 2024 Judge Case Conference, which were later reflected in the judgment as the operative directions for obtaining signature specimens for HSA. The directions required both parties to work with BCS for a list of at least 15 documents that the parties can agree Mr Ang would clearly have signed. The list was also required to include documents for which Mr Ang had not seen the signatures. Procedurally, the parties were to write to BCS within one week; BCS was to respond within three weeks; and Mr Ang was to provide his position on the list three weeks thereafter.
Practically, the outcome was a structured, integrity-focused specimen-selection process. It ensured that the handwriting expert would receive a sufficiently broad and credible set of specimen signatures, while preserving procedural fairness by giving Mr Ang an opportunity to comment on the documents identified by BCS. The court’s approach also clarified that, under the Evidence Act framework, the defendant does not have a right to select specimen signatures for comparison merely because authorship is disputed.
Why Does This Case Matter?
This decision is significant for practitioners because it addresses a recurring problem in disputed-signature litigation: how to prepare specimen signatures for handwriting experts in a way that is both reliable and procedurally fair. The court’s emphasis on “integrity in the process” signals that specimen selection is not a neutral administrative task. It can affect the perceived and actual reliability of expert analysis, and courts will scrutinise processes that allow one party to control the specimen pool.
From an evidence-law perspective, the case clarifies the relationship between authenticity of authorship and party control. While the court fully accepted that specimen signatures must be authentic, it rejected the argument that authenticity concerns automatically entitle a party to select the specimen documents. The court’s reliance on s 75 of the Evidence Act reinforces that comparison signatures are governed by proof to the court’s satisfaction, rather than by unilateral party choice.
For litigators, the practical implications are clear. Where handwriting analysis is likely to be determinative, parties should anticipate specimen-selection disputes and propose processes that preserve integrity—such as using independent record custodians or corporate service providers, ensuring a sufficiently large and varied specimen set, and building in a mechanism for the disputed party to raise objections about specific documents. The case also illustrates the value of early, court-supervised directions in expert-evidence workflows, particularly where cross-border documents and originals are involved.
Legislation Referenced
Cases Cited
- Tung Kean Hin & Another (as executor for the estate of Tung Leong Geok, deceased) v Yuen Heng Phong (as administrator for the estate of See Ngan Sang @ Lee Ngan Sang) [2019] 2 MLJ 334
Source Documents
This article analyses [2025] SGHC 12 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.